What PT-141 is. And where it comes from
PT-141 (bremelanotide) is a synthetic 7-amino-acid cyclic peptide derived from Melanotan II. It was originally investigated as a tanning agent; researchers noticed significant sexual arousal as an unexpected side effect during early trials. Development pivoted to sexual dysfunction, ultimately yielding a 2019 FDA approval for hypoactive sexual desire disorder (HSDD) in premenopausal women under the brand name Vyleesi.
Unlike PDE5 inhibitors (sildenafil, tadalafil) which work peripherally on blood vessels, PT-141 works centrally. Activating melanocortin receptors in the brain that are involved in sexual motivation and desire.
Mechanism, in plain English
PT-141 activates melanocortin receptors, specifically MC3R and MC4R, in the central nervous system. These receptors are expressed in hypothalamic regions involved in sexual behavior and motivation. The downstream signaling modulates dopaminergic pathways associated with desire and arousal. This is a fundamentally different mechanism from vascular or hormonal approaches.
What the evidence shows
RECONNECT trials. Clayton et al. 2019 (Obstetrics & Gynecology). Two phase 3 RCTs in 1,267 premenopausal women with HSDD. Bremelanotide showed statistically significant improvements in satisfying sexual events and sexual desire scores vs placebo, supporting FDA approval.
Evidence in men is limited to earlier-phase studies and off-label use. No phase 3 RCT has been completed in male HSDD or erectile dysfunction.
FDA status (this month)
Bremelanotide (Vyleesi) is FDA-approved for the treatment of hypoactive sexual desire disorder (HSDD) in premenopausal women. It is not FDA-approved for men. Last reviewed 2026-08-09.
Common synonyms researchers use
PT-141 · Bremelanotide · Vyleesi · melanocortin receptor agonist
Safety & adverse-event landscape
Most common adverse effects in RECONNECT trials: nausea (40%), flushing (20%), injection site reactions, headache, vomiting. Nausea was the leading cause of discontinuation. Bremelanotide can cause transient increases in blood pressure and decreases in heart rate, it is contraindicated in patients with cardiovascular disease. Not for use with alcohol or with other agents that affect blood pressure. Always consult a qualified healthcare provider.
Frequently asked questions
Want the complete sexual function and libido peptide reference?
The Peptexa Top-5 free guide covers the most-studied compounds with the clearest evidence, mechanism, evidence level, and FDA status for each.
What the preclinical evidence shows
The bulk of the published evidence comes from rodent models, tendon transection and Achilles repair, vascular ligation, NSAID-induced gut damage, and fistulizing colitis models. Effects have been reported as positive in tendocyte outgrowth assays, in vascular angiogenesis assays, and in rat colitis models. The most-cited review is Sikiric (2018) in Current Pharmaceutical Design.
Human published data is limited to small case-series reports and registry submissions. There are no large randomized controlled trials to date. The bulk of the discussion in online health communities reflects animal extrapolation, not human-trial data.
Strong preclinical animal research supports investigation into tendon, ligament, and gastrointestinal healing. Human clinical evidence remains limited despite extensive anecdotal use.
FDA status (this month)
BPC-157 is not FDA-approved for any human indication. On July 23-24, 2026, an FDA Pharmacy Compounding Advisory Committee reviewed several peptides including BPC-157 and voted to recommend reviewing whether compounding pharmacies may be allowed to produce them. A rule-making step would be required before any compounding access is granted. And that step is not FDA approval. Coverage: NYT briefing. Last reviewed 2026-08-09.
Common synonyms researchers use
BPC 157 · BPC-157 · Body Protection Compound 157 · PL-14736 (early proprietary designation in the Sikiric et al. literature).
Safety & adverse-event landscape
In the published preclinical literature, BPC-157 has been administered to rodents over short and medium-term protocols without reported mortality. Adverse-event data in humans is limited. The compound's interaction with nitric oxide pharmacology suggests theoretical considerations with vasodilator and cardiovascular medications, consult your provider if you take any.
Peptexa is an educational resource. We do not provide dosing guidance, sourcing recommendations, or protocol advice. Always consult a qualified healthcare provider before any decision that involves a peptide, supplement, or therapeutic compound.
Frequently asked questions
Want this in your inbox weekly?
Get the Peptexa Top-5 free, five compounds, mechanism-led. One email a week. No spam.
The Peptexa Top-5 Free Guide
Five compounds. Mechanism-led. Evidence-ranked. Free PDF, no email required.
Get the Free Guide →